Features | Partner Sites | Information | LinkXpress
Sign In
SIEMENS DIAGNOSTICS

Sequencing System Monitors Low Frequency HIV Variants

By Labmedica International staff writers
Posted on 05 Jan 2009
Scientists have used a genome sequencer system to monitor low frequency human immunodeficiency virus (HIV) variants from human samples.

Correct determination of HIV tropism is critical for the administration of a new class of drugs called CCR5 antagonists used for the treatment of AIDS. HIV tropism refers to the type of cell the HIV virus infects, as determined by coreceptors that the virus employs for entry into the cell. Determining the coreceptor that a HIV strain uses, CCR5, CXCR4, or a combination of both, is a critical component of monitoring and treating HIV.

454 Life Sciences (Branford, CT, USA), a Roche company (Indianapolis, IN, USA) announced that a team of scientists from the British Columbia (BC) Center of Excellence in HIV/AIDS (Vancouver, Canada) and the University of British Columbia, (Vancouver, Canada) used the company's genome sequencer FLX system in a recent study of HIV tropism. The 454 sequencing system has simple, unbiased sample preparation and long, highly accurate sequence reads, including paired-end reads. The technology of the sequencing system has enabled hundreds of studies in diverse fields including cancer, infectious diseases, and drug discovery

Preliminary results of the study found that conventional genotyping methods lack sufficient sensitivity for detection of the CXCR4 variant, which is a contraindication for administering CCR5 antagonists. By using deep sequencing, the team was able to quantify low-frequency variants associated with poor response to CCR5 antagonists and accurately determine HIV tropism across all individuals' samples.

The 454 sequencing system has a simple, unbiased sample preparation and long, highly accurate sequence reads, including paired-end reads. The technology of the sequencing system has enabled hundreds of studies in diverse fields including cancer, infectious diseases, and drug discovery

Preliminarily results of the study were presented by Dr. Richard Harrigan (lab director at the BC Center for Excellence in HIV/AIDS) at the HIV DART (Duke University AIDS Research and Treatment Center) conference in Puerto Rico on December 10, 2008. Dr. Harrigan explained, "The sensitivity of the genome sequencer FLX platform allowed us to monitor HIV sequence variation from 48 or 96 individuals´ samples simultaneously, and still have far greater ability to spot minority variants than using standard approaches."

He added that this has important implications for therapy monitoring. "The fact that the genome sequencer FLX system gives a quantitative measure of sequence variance within a sample is a bonus.”

The genome sequencer FLX system, powered by 454 sequencing, enables discoveries in de novo sequencing, resequencing of whole genomes and target DNA regions, metagenomics, and RNA analysis. Featuring a unique combination of long reads, exceptional accuracy, and ultra-high throughput, the genome sequencer FLX system delivers a comprehensive result at a low total cost, giving it excellent value for any next-generation sequencing platform.

Related Links:
454 Life Sciences
Roche
British Columbia Center of Excellence in HIV/AIDS



comments powered by Disqus

Channels

Genetic Tests

view channel
Image: Histopathology of a hepatoblastoma, a type of liver cancer found in infants and young children (Photo courtesy of Nephron).

Gene Identified That Promotes Childhood Cancers

A gene has been identified that contributes to the development of several childhood cancers and this could lead to new strategies for targeting certain childhood cancers at a molecular level.... Read more

Immunology

view channel
Image: The Zinc Transporter 8 Autoantibody (ZnT8Ab) enzyme-linked immunosorbent assay (ELISA) kit (Photo courtesy of KRONUS).

Autoantibody Test Helps Diagnose Type 1 Diabetes

The first zinc transporter 8 autoantibody (ZnT8Ab) test has been approved for marketing and the test can help determine if a person has diabetes mellitus type 1 and not another type of diabetes.... Read more

Industry News

view channel

Physician Office IVD Sector Nears USD 2.5 Billion

The physician office laboratory (POL) in vitro diagnostic (IVD) market grew to USD 2.44 billion in 2013, from just over USD 2 billion four years ago, according to the 2014 market study report “Physician Office Laboratory Markets, 3rd Edition” from Kalorama Information (New York, NY, USA). Considered in its POL analysis... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.